Revenues / Financials
- 27% YoY growth in Revenue (4400 crores)
- 22% YoY growth in PAT ( 1212 crores)
- 37% EBIT Margins
- 26% PAT Margin
- Zero Long term borrowing
- Gross Block 7,833 crores
- Capex 522 crore (228 crore in FY21, 194 cr in FY20)
Intellectual Capital
0.95 cr average revenue per employee
29 ANDAs filed – 19 approved
56 Customer Audits
11 DMFs filed
19% Attrition rate
India 60% YoY Growth
Europe 59% YoY Growth
Canada 26% YoY Growth
USA 13% YoY Growth
Australia 7% YoY Growth
India saw an impressive performance (revenue growth of 60% in FY 2021-22 compared to FY 2020-21), primarily on account of volume growth of existing products (India is the only B2C play rest all is B2B )
ROW – The biggest contributors were the LatAm, GCC and other Asian countries. Very positive response from the markets we have recently entered, including Singapore, Israel, Saudi Arabia, and CIS countries
Revenue contribution from new launches
236 crore in FY 22 (Dip in revenue from new launches )
366 crore in FY 21
229 crore in FY 20
Existing Products / New Launches
- Launched a total of 44 product SKUs (29 molecules) during FY 2021-22. Other core markets of Europe, Canada, Australia and New Zealand have also demonstrated strong demand for our products
- Micafungin Sodium, Ketorolac Tromethamine, Heparin Sodium, Ziprasidone, and Dexmedetomidine are some of the key products driving our growth in our core markets.
During the year under review, also successfully launched Caspofungin Acetate and Enoxaparin Sodium (Multi- Dose Cartridge with Pen Device) in the domestic market.
Along with other products such as Heparin Sodium, Rocuronium Bromide, and Dexmedetomidine, Enoxaparin Sodium was a key contributor to growth during the year.
We also registered our products Dexmedetomidine, Ertapenem and Tigecycline in new geographies.
Manufacturing Capital
- 28 production lines**
- 1,000 million units Finished formulation capacity (800 Million units last year)
- Added additional approved lines for our existing products to help reduce manufacturing risks
- Investing towards creating robust infrastructure for Biologic CDMO. (Dedicated team in place to take this forward, exploring opportunities to collaborate with our partners (Fosun ) and other companies to expedite our entry in this space)
- Vertically integrated injectable’s manufacturing capabilities
- We are also developing our Biotech Drug Substance Facility for biosimilars and exploring collaboration opportunities with established biosimilars producers (Genome Valley Hyderabad plant )
- Supply chain efficiencies are backed by our API production capacity, which ensures a secure supply of critical production inputs for our key products.
Human Capital
- 4,639 Employees as on March 31, 2022 ( 315 in r&d and 1449 in QA&QC – 31.24% of the work force is in QA&QC)
Management
25 Years of average experience of top management in the pharmaceutical industry
R&D Spend
- 86% YoY growth in R&D expenditure to strengthen product pipeline and enhance capabilities (Mainly into Biosimilar capacities setup ? )
Gland Strengths
- Complex injectable’s , oncology, and ophthalmology segments
- Drug Delivery methods – liquid vials, lyophilised vials, pre-filled syringes, ampoules,bags, and drops
New Capabilities (Work in progress )
- Complicated injectables such as peptides,long-acting injectables, suspensions, hormonal, pens and cartridges medicines.
KMP Remuneration
Note :FY20-21 89.43 cr
Mr. Srinivas Sadu was reappointed as MD & CEO for a further period of five years w.e.f. 25th April,
2022 vide resolution passed by the Shareholders through postal ballot on 20th April, 2022.
Industry Overview
Key Takeaways
- Entered markets in China by leveraging the credentials of our parent company, Fosun Pharma
- Spending on modern therapies by setting up biologics infra.
- Working on new drug delivery methods
- Since China is mostly tender driven business how Gland can piggy back on parents strong presence is something we have to watch out for.
- Since Bio CDMO is new space they are ready with capabilities, what is their right to win is something interest to watch
- They can gain more from Fosun in terms by strengthening KSM supply chain, this is the most important variable to avoid the issues like shortage syringes or other materials that are the life blood of business.
| Subscribe To Our Free Newsletter |
